BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3718544)

  • 21. Dehydrogenase binding by tiazofurin anabolites.
    Goldstein BM; Bell JE; Marquez VE
    J Med Chem; 1990 Apr; 33(4):1123-7. PubMed ID: 1969483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic action of tiazofurin and genistein on growth inhibition and differentiation of K-562 human leukemic cells.
    Li W; Weber G
    Life Sci; 1998; 63(22):1975-81. PubMed ID: 9839541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxicity of tiazofurin and its arabinose and xylose analogues in K562 cells.
    Zhen W; Jayaram HN; Marquez VE; Goldstein BM; Cooney DA; Weber G
    Biochem Biophys Res Commun; 1991 Oct; 180(2):933-8. PubMed ID: 1683233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Green RM; Stewart DJ; Maroun JA
    Invest New Drugs; 1986; 4(4):387-94. PubMed ID: 3583646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
    Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
    J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of HL60 cell differentiation by tiazofurin and its analogues: characterization and efficacy.
    Goldstein BM; Leary JF; Farley BA; Marquez VE; Levy PC; Rowley PT
    Blood; 1991 Aug; 78(3):593-8. PubMed ID: 1650262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
    Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
    Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
    Sokoloski JA; Sartorelli AC
    Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase.
    Fridland A; Connelly MC; Robbins TJ
    Cancer Res; 1986 Feb; 46(2):532-7. PubMed ID: 3000575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique bioactivation of tiazofurin--studies with resistant cells.
    Kuttan R
    Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.
    Jayaram HN; Lapis E; Tricot G; Kneebone P; Paulik E; Zhen W; Engeler GP; Hoffman R; Weber G
    Int J Cancer; 1992 May; 51(2):182-8. PubMed ID: 1568787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical issues in chemotherapy with tiazofurin.
    Weber G
    Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs.
    Arnold ST; Jayaram HN; Harper GR; Litterst CL; Malspeis L; DeSouza JJ; Staubus AE; Ahluwalia GS; Wilson YA; Cooney DA
    Drug Metab Dispos; 1984; 12(2):165-73. PubMed ID: 6144481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein.
    English D; Rizzo MT; Tricot G; Hoffman R
    J Immunol; 1989 Sep; 143(5):1685-91. PubMed ID: 2547872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
    Trump DL; Tutsch KD; Koeller JM; Tormey DC
    Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.
    Jayaram HN; Murayama K; Pillwein K; Zhen W; Weber G
    Cancer Chemother Pharmacol; 1992; 31(2):93-6. PubMed ID: 1451238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of tiazofurin in dogs.
    Obeng EK; Vallner JJ; Cadwallader DE; Tackett RL
    Biopharm Drug Dispos; 1987; 8(2):125-32. PubMed ID: 3593893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of resistance to 6-aminonicotinamide.
    Saunders PP; Muhs MA; Arimilli S
    Anticancer Res; 1996; 16(2):843-8. PubMed ID: 8687139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.